Recorded fact · drug.label_indication
drug.label_indication for dabrafenib-mesylate|thyroid-cancer
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 1bdf2fd7 resolves to.
The record
| Fact id | 1bdf2fd77d0f6bc767230f6f |
|---|---|
| Entity | drug: dabrafenib-mesylate|thyroid-cancer |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260520 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 108f433736af19a3282517713919c484e2acd1aa6fb06c4bb72afd7ccd3fedac.
The value
{
"ingredient": "Dabrafenib Mesylate",
"conditionId": "thyroid-cancer",
"conditionName": "Thyroid cancer",
"matchedAlias": "thyroid cancer",
"context": "indication",
"brand": "Tafinlar",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea",
"labelEffectiveTime": "20260520",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: b5e1db4708c512f254622e44cdd4a823a459275764331fd47b7474988fe75d4d.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.